Obesity phenotype and patient-reported outcomes in moderate and severe chronic kidney disease: a cross-sectional study from the CKD-REIN cohort study.


Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Jul 2019
Historique:
accepted: 11 01 2019
pubmed: 20 1 2019
medline: 23 8 2019
entrez: 20 1 2019
Statut: ppublish

Résumé

To evaluate the association between obesity phenotypes and health-related quality of life (HRQoL) in non-dialysis-dependent CKD patients. Data from the national CKD-REIN cohort which included 3033 patients with stage 3-4 CKD were used. Patients were divided into three groups: non-obese (NO) patients (BMI < 30 kg/m A total of 2693 patients completed the self-administered questionnaires. MHO patients accounted for 3.4% of the cohort and for 12% of obese patients. In the NO group, average HRQoL scores were 77.2 ± 15.9 for symptoms, 83.5 ± 16.5 for effects, 76.8 ± 22.7 for burden, 43.5 ± 9.7 for PCS, and 47.9 ± 7.0 for MCS. In the multivariate analysis, scores were similar in MHO and NO patients, but significantly different with those in MUO patients: symptoms (- 0.7; p = 0.71 vs. - 3.0; p = 0.0025), effects (+ 1.2; p = 0.57 vs. - 4.3; p < 0.0001), burden (+ 2.7; p = 0.31 vs. - 3.6; p = 0.0031), and PCS (- 0.6; p = 0.58 vs. - 4.3; p < 0.0001). MCS was not associated with obesity phenotypes. This study demonstrated an association between obesity phenotypes and QoL in non-dialysis-dependent CKD patients. MUO patients had worse QoL than NO and MHO patients even after adjustment on comorbidities.

Identifiants

pubmed: 30659448
doi: 10.1007/s11136-019-02110-2
pii: 10.1007/s11136-019-02110-2
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1873-1883

Références

Metabolism. 2001 Dec;50(12):1499-504
pubmed: 11735101
Am J Kidney Dis. 2003 Mar;41(3):605-15
pubmed: 12612984
Am J Kidney Dis. 2003 Jun;41(6):1286-92
pubmed: 12776282
Kidney Int. 2003 Jul;64(1):339-49
pubmed: 12787427
Kidney Int. 2003 Nov;64(5):1903-10
pubmed: 14531826
Am J Kidney Dis. 2004 Nov;44(5 Suppl 2):54-60
pubmed: 15486875
Kidney Int. 2004 Nov;66(5):2047-53
pubmed: 15496178
Diabetes Metab. 2004 Dec;30(6):569-72
pubmed: 15671927
Semin Dial. 2005 Mar-Apr;18(2):91-7
pubmed: 15771651
Am J Kidney Dis. 2005 Apr;45(4):658-66
pubmed: 15806468
J Clin Epidemiol. 2005 Jun;58(6):595-602
pubmed: 15878473
J Clin Endocrinol Metab. 2006 Aug;91(8):2906-12
pubmed: 16735483
Scand J Public Health. 2007;35(5):510-5
pubmed: 17852988
Nephrol Dial Transplant. 2008 Mar;23(3):998-1004
pubmed: 17911092
Nephrol Ther. 2007 Oct;3(6):372-83
pubmed: 17919640
Qual Life Res. 2008 Feb;17(1):1-9
pubmed: 18044008
Lancet. 2008 Oct 11;372(9646):1281-3
pubmed: 18929889
Clin J Am Soc Nephrol. 2009 Aug;4(8):1293-301
pubmed: 19643926
Kidney Int. 2009 Nov;76(9):946-52
pubmed: 19675529
BMC Public Health. 2010 Nov 24;10:723
pubmed: 21106050
Kidney Int. 2011 Jul;80(1):17-28
pubmed: 21150873
Health Qual Life Outcomes. 2012 Jun 18;10:71
pubmed: 22710013
Diabetes Care. 2013 Aug;36(8):2388-94
pubmed: 23491523
Ethn Dis. 2013 Spring;23(2):202-9
pubmed: 23530302
Rev Endocr Metab Disord. 2013 Sep;14(3):219-27
pubmed: 23928851
Nephrol Dial Transplant. 2014 Aug;29(8):1500-7
pubmed: 24064325
Obes Rev. 2014 Jun;15(6):504-15
pubmed: 24661566
Eur Heart J. 2015 Mar 1;36(9):551-9
pubmed: 24670711
Kidney Int. 2015 Nov;88(5):950-7
pubmed: 26221752
J Am Soc Nephrol. 2016 Jul;27(7):2135-47
pubmed: 26701975
Clin Nutr. 2017 Jun;36(3):853-860
pubmed: 27184975
Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1154-62
pubmed: 27246012
PLoS One. 2016 Dec 19;11(12):e0168491
pubmed: 27992595
J Adolesc Health. 2017 Jul;61(1):107-114
pubmed: 28363717
BMC Nephrol. 2018 Jan 15;19(1):11
pubmed: 29334904
Nephrol Dial Transplant. 2019 Feb 1;34(2):277-286
pubmed: 29635335
Qual Life Res. 1994 Oct;3(5):329-38
pubmed: 7841967
Am J Prev Med. 1994 Mar-Apr;10(2):77-84
pubmed: 8037935

Auteurs

M L Schweitzer (ML)

INSERM, CHU Nancy, Université de Lorraine, CIC-1433, Epidémiologie clinique, 54000, Nancy, France.

B Stengel (B)

CESP Centre for Research in Epidemiology and population Health, UMRS 1018, University Paris-Saclay, University Paris Sud, UVSQ, 94807, Villejuif, France.

K Legrand (K)

INSERM, CHU Nancy, Université de Lorraine, CIC-1433, Epidémiologie clinique, 54000, Nancy, France.
Université de lorraine, 4360 APEMAC, 54000, Nancy, EA, France.

S Briançon (S)

Université de lorraine, 4360 APEMAC, 54000, Nancy, EA, France.

C Jacquelinet (C)

CESP Centre for Research in Epidemiology and population Health, UMRS 1018, University Paris-Saclay, University Paris Sud, UVSQ, 94807, Villejuif, France.
Agence de la Biomédecine, Saint-Denis, France.

C Combe (C)

Service de Néphrologie Transplantation Dialyse Aphérèse, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
Inserm, U1026, Université Bordeaux Segalen, Bordeaux, France.

D Fouque (D)

Nephrology Department, Centre Hospitalier Lyon-Sud, Univ Lyon, UCBL, Carmen, 69495, Pierre-Bénite, France.

Z A Massy (ZA)

CESP Centre for Research in Epidemiology and population Health, UMRS 1018, University Paris-Saclay, University Paris Sud, UVSQ, 94807, Villejuif, France.
Nephrology Department, CHU Ambroise Paré, Boulogne, France.

M Laville (M)

Nephrology Department, Centre Hospitalier Lyon-Sud, Univ Lyon, UCBL, Carmen, 69495, Pierre-Bénite, France.

L Frimat (L)

Nephrology Department, CHU Nancy, Vandoeuvre-lès-Nancy, France.

C Ayav (C)

INSERM, CHU Nancy, Université de Lorraine, CIC-1433, Epidémiologie clinique, 54000, Nancy, France. c.ayav@chru-nancy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH